Tumor-associated antigen-specific T cell response (TAA-specific T cell response)

A tumor-associated antigen (TAA)-specific T cell response is a complex immunological process where the adaptive immune system identifies and attacks malignant cells based on the expression of specific proteins (National Cancer Institute, 2023). These antigens can be products of mutated genes (neoantigens), overexpressed self-proteins, or proteins with restricted expression patterns, such as cancer-testis antigens. The response is mediated primarily by CD8+ cytotoxic T lymphocytes and CD4+ helper T cells that recognize TAA peptides presented by Major Histocompatibility Complex (MHC) molecules (PubMed, PMID: 31019211). In the context of oncology, this response is the primary mechanism through which many immunotherapies, including checkpoint inhibitors and cancer vaccines, exert their anti-tumor effects (Nature Reviews Cancer, 2021). While a robust TAA-specific response is associated with better clinical outcomes, it is often suppressed by the tumor microenvironment through mechanisms like PD-L1 expression or the recruitment of regulatory T cells. Therapeutic interventions aim to overcome this suppression or artificially induce the response via adoptive cell transfer or engineered T cell receptor (TCR) therapies. Monitoring this response through specialized biomarkers is crucial for evaluating the efficacy of immunotherapeutic agents (Journal for ImmunoTherapy of Cancer, 2020).

Other names

Anti-tumor T cell responseTAA-specific immunityTumor-specific T cell responseAntigen-specific T cell activation

Enhancement of T cell activation and recruitment through checkpoint inhibition, vaccination, or adoptive transfer.